Вестник Ассоциации пульмонологов Центральной Азии Ҷилди 13 № 8 (2025) · Саҳифаҳои 21-26
COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY
Mullokulov J.J., Akhmedov Kh.S.
Аннотатсия
Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF-α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.
reactive arthritis, baricitinib, adalimumab, DAREA, BASDAI.
Манбаи метамаълумот: бойгонии OAI-PMH-и маҷалла · Sindex матни пурраро нигоҳ намедорад, ба манбаъ пайванд медиҳад.